TCR+CD8+ T cell in health and disease: a novel and functionally active subpopulation of T-cells enriched within the gut

Kadivar, M.; Petersson, J.; Bekiaris, Vasileios; Marsal, J.; Svensson, L.

Published in:
European Journal of Immunology

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
These 'conventional' T cells express either CD4 or CD8αβ co-receptors and can be reliant on these molecules for the recognition of MHC-II and MHC-I respectively. In the last two decades, T cells bearing receptors reactive to lipid and small molecule antigens have been discovered. These include Mucosal-Associated Invariant T (MAIT) cells, which are restricted by the monomorphic MHC molecule MR1.

Using MR1-tetramers we showed that MAIT cell co-receptor expression is discordant with conventional T cells. MAIT cells predominantly express CD8αα or to a lesser extent can be deficient of co-receptor molecules. The high frequency of CD8α+ MAIT cells suggests that the CD8 co-receptor may influence immune outcomes in this population of cells. Using a CD8α transduced cell line, we have determined that CD8αα is capable of binding to MR1-tetramers in the absence of a T cell receptor (TCR) and fails to bind to MR1-tetramers mutated at residues shown to abrogate the CD8 interaction with MHC-I. Our observations suggest that MAIT cells use the CD8 co-receptor in a similar manner as conventional T cells to bind MHC-I, whereby CD8 can bind MR1 to enhance the overall avidity of the MAIT TCR interaction with MR1. We aim to characterize the CD8 interaction with MR1 quantitatively and determine its importance in MAIT cell biology.

73
TCRγδ*CD8αβ+ T cell in health and disease: a novel and functionally active subpopulation of T cells enriched within the gut
Kadivar, M.1,2, Petersson, J.1, Bekiaris, V.2, Marsal, J.3, Svensson, L.1
1Lund University, Medical Faculty, Immunology, Lund, Sweden, 2Technical University of Denmark, DTU Vet., Copenhagen, Denmark, 3Lund University, Skane University Hospital, Gastroenterology, Lund, Sweden

γδ T-cells have been implicated in the pathogenesis of immune-mediated diseases such as inflammatory bowel disease (IBD). However, a potential role of different immune cell subsets in IBD and also in the process of mucosal healing upon treatment is unknown. γδ T-cells have been divided into CD8αα* and CD8αβ* T-cells. By using flow cytometry and RT-PCR, we described for the first time a novel subset of human γδ T-cells expressing CD8αβ heterodimers on their surface. We found that these TCRγδ*CD8αβ+ T-cell subset exist in both human peripheral blood as well as in the gut, however they were differentially enriched within the gut. TCRγδ*CD8αβ+ T-cells displayed high cytotoxic activity by expressing Fas Ligand on their surface and also producing Granzyme B and Perforin. We showed that these cells can produce INFγ and TNFα but they did not show the ability to produce IL-17 in healthy individuals. In patients with IBD, we found a decrease in the percentage of intestinal CD8αβ+ γδ T-cells compared to healthy controls. Moreover, the percentage of TCRγδ*CD8αβ+ T-cells out of γδ T-cells showed a negative correlation with Crohn’s disease activity. Three months of anti-TNFα (adalimumab) therapy increased the percentage of TCRγδ*CD8αβ+ T-cells close to the level of healthy controls. These results suggest that TCRγδ*CD8αβ+ T-cells might possibly play a role in gut inflammation and also intestinal wound healing after anti-TNFα treatment. These results are likely to have implications for the development of novel therapies to treat mucosal inflammatory diseases.

74
A broad family of MR1-restricted T cells
Gherardin, N.A.1,2,3, Keller, A.N.4,5, Woolley, R.E.4,5, Le Nours, J.4,5, Ritchie, D.S.2,6, Neeson, P.J.2, Birkinshaw, R.W.4,5, Eckle, S.B.1, Waddington, J.N.1, Liu, L.7,8, Fairlie, D.P.1,8, McCluskey, J.1, Pellicci, D.G.1,3, Ulrich, A.P.1,3, Rossjohn, J.4,5,9, Godfrey, D.I.1,3
1Peter Doherty Institute for Infection and Immunity at The University of Melbourne, Department of Microbiology and Immunology, Melbourne, Australia, 2The Peter MacCallum Cancer Centre, Cancer Immunology Research, East Melbourne, Australia, 3ARC Centre of Excellence in Advanced Molecular Imaging, The University of Melbourne, Melbourne, Australia, 4Monash University, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Clayton, Australia, 5ARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Australia, 6University of Melbourne, Department of Medicine, Melbourne, Australia, 7University of Queensland, Division of...